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Objective: Recurrent intrathoracic thymomas may have an unpredictable behavior. Cell-cycle protein expression
has proven useful in predicting outcome in a variety of neoplasms. We investigated its potential prognostic im-
portance in recurrent intrathoracic thymomas.
Methods:We reviewed the case histories of 25 consecutive patients operated on between 1987 and 2004 for in-
trathoracic recurrence (7 mediastinal, 18 nonmediastinal) after radical thymomectomy. Complete resection was
performed in 14 patients. In the other 11 patients incomplete resection was followed by chemotherapy and radio-
therapy. Expression of cell-cycle proteins (p53, p21, and p27) was assessed by immunohistochemistry in spec-
imens retrieved from both initial and recurrent thymomas. Univariate and multivariate analysis for prognostic
factors present at the time of the recurrence was performed.
Results: Eight of 14 patients who underwent complete resection had a second recurrence after a mean free inter-
val of 20  9 months, and a new complete resection was reperformed in 4. After incomplete resection, chemo-
therapy and radiotherapy allowed total remission in 4 subjects and only 1 of these had a second recurrence.
Survival after surgery of the recurrence was negatively influenced by incomplete recurrence resection (P ¼
.03), first disease-free interval less than 24 months (P ¼ .03), high p53 (P ¼ .04), low p21 (P ¼ .02), low p27
(P ¼ .003) expressions, and combination of these proteins (p53 high, p21 low, p27 low expression) (P ¼
.0001). Multivariate analysis selected the triple combination of cell-cycle protein expression as the most signif-
icant prognostic variable (P ¼ .02, odds ratio ¼ 11.96, 95% confidence interval ¼ 1.39–102.63).
Conclusions: Cell-cycle protein expression, and namely the combination of high p53, low p21, and low p27
expression, may have a potential prognostic importance in recurrent intrathoracic thymomas.Thymoma recurrence is rare, occurring in 10% to 30% of
patients after complete resection of primary tumor.1-5
Some thymomas are more prone to recur than others. The be-
havior of the recurrences may change during time, with
a long period of slow growth and rapid unpredictable pro-
gression. When feasible, surgical resection of the recurrence
is still considered the treatment of choice6-11 but is some-
times inadequate to prevent further relapses and thus com-
bined treatments are preferred.12,13 To establish the most
appropriate therapy, it would seem desirable to have reliable
indicators to predict the probability of recurrence. The
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doi:10.1016/j.jtcvs.2008.11.04840 The Journal of Thoracic and Cardiovascular Surgpresent prognostic parameters, that is, current staging,5,14,15
tumor size,16 and World Health Organization (WHO) histol-
ogy classification,17-19 have demonstrated some and yet not
conclusive relationships with recurrence behavior.
In the past decade, significant progress has been made as
a result of a better understanding of the biological processes
behind neoplasm development.20,21 Cell-cycle control has
been the focus of extensive research.20 A key role is played
by cell-cycle kinases, relatively small proteins regulated by
the arrangement in a multimeric complex with larger pro-
teins, called ‘‘cyclins’’ because of their cyclical expression
and degradation during the cell cycle. Cell-cycle kinase/cy-
clin complexes are negatively modulated by interaction
with a family of small proteins called cell-cycle kinase inhib-
itors, namely p21 and p27.20,21 The p53 tumor suppressor
gene is also involved in cell-cycle checkpoints, acting as
a transcription factor for several cell-cycle regulatory
proteins, including the p21 gene.21We have recently demon-
strated the role of the cell-cycle protein expression and espe-
cially of p27 expression in the prognosis of radically resected
thymomas.22
The aim of this study is to evaluate the potential prognos-
tic importance of the expression of p53, p21, and p27 cell-
cycle proteins in a series of recurrent intrathoracic thymomas
and compare these factors with traditional prognosticators.ery c July 2009
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METHODS
Between January 1987 and December 2004, a total of 25 (14male and 11
female) patients previously operated on for thymoma in our department
were reoperated on for intrathoracic recurrences. This number corresponds
to approximately one quarter of the patients undergoing intentional com-
plete thymoma resection (n¼ 97) and three quarters of those having a recur-
rence (n ¼ 33). Clinical and pathologic data (ie, gender, age, presence of
myasthenia gravis, operative notes of the primitive thymoma and recurrence
procedures, postoperative complications, pathologic issues, postoperative
therapy, recurrence pattern, and long-term follow-up information) were re-
trieved retrospectively (Table 1).
Staging was based on surgical and pathologic criteria described by Ma-
saoka and associates5 and achieved retrospectively by reviewing the patho-
logic and operative notes of the surgeon. The morphologic classification of
the thymomas was reassessed according to WHO17 specifications. Patients
with primitive histology of thymic carcinomas (WHO C class) were ruled
out. An essential prerequisite for study inclusion was the proved radical sur-
gical resection of the initial thymoma. Patients with distant metastases or un-
dergoing initial thymomectomy after neoadjuvant radiotherapy and/or
chemotherapy for initially unresectable thymomas were excluded.
Mean age at initial thymomectomy was 47 years (range, 27–63 years).
Five thymomas were staged as I, 11 as II, and 9 as III. All 9 patients at stage
III and 2 at stage II underwent prophylactic postoperative treatment: a com-
bination of radiotherapy and chemotherapy in 4 patients, radiotherapy alone
in 3 patients, and chemotherapy alone in 2 patients. Chemotherapy con-
sisted of three cycles of cisplatin (75 mg/m2, day 1) and etoposide (120
mg/m2 on days 1, 3, and 5) every 3 weeks. A dose of 40 Gy was usually
administered fractioned in 5 doses per week in 3 weeks. All patients were
able to complete the cycles with transient side effects.
Follow-up
Recurrence was defined as any evidence of tumor detected by imaging or
biopsy during follow-up. Patients with mediastinal pattern of recurrences
were defined as those with recurrences located in the mediastinum or arising
from this region. Nonmediastinal pattern of recurrence was considered for
patients whose recurrences were confined only in extramediastinal struc-
tures (ie, parietal pleura, lung, diaphragm).
Follow-up consisted of periodic visits in an outpatient clinic every 6
months for the first 2 years after initial thymomectomy and then yearly.
In cases in which patients could not be reached, their primary care physician
or neurologist was contacted. Patients with incomplete follow-up informa-
tion were excluded from the study.
Recurrence Resection
Clinical evolution of the study group patients is summarized in Figure 1.
Seven patients had amediastinal pattern and 18 nonmediastinal: lung (n¼ 3),
diaphragm (n¼ 4), parietal pleura (n¼ 6), and combined (n¼ 5). Mean first
disease–free interval was 36  22 months. Mediastinal recurrences devel-
oped earlier than nonmediastinal ones (mean interval 28  14 vs 39  24
months; P¼ .02). No correlation between recurrence patterns and primitive
stage was found (data not shown). The recurrences were asymptomatic in 15
patients and the diagnosis was revealed by computed tomographic scan ab-
normalities. Chest symptoms were present in 6 patients, and myasthenia
gravis recurrence was present in 4. Owing to the large extent of the recur-
rence, 7 patients received preoperative chemotherapy with the same proto-
col used after the primitive surgery. The new resection was performed
through median sternotomy (n ¼ 2), lateral thoracotomy (n ¼ 21), andThe Journal of Thoracic andbilateral staged thoracotomies (n¼ 2). Complete resection of the recurrence
was accomplished in 4 mediastinal and 10 nonmediastinal recurrences
(lung, n ¼ 2; diaphragm, n ¼ 3; and parietal pleura, n ¼ 5). Chemotherapy
was usually performed after complete reresection as well.
The remaining 11 patients (3 mediastinal and 8 nonmediastinal) under-
went incomplete resection all followed by radiotherapy (55Gy total dosage)
and chemotherapy. The response to chemotherapy and radiotherapy was
complete with no evidence of residual disease in 4 of these patients, partial
in 4, and without effects in 3.
Immunohistochemistry
Specimen reanalysis was approved and authorized by our institutional
review board. Expression of cell-cycle proteins (p21, p27, and p53) was as-
sessed in specimens retrieved at both primary and recurrence procedures us-
ing immunohistochemistry. In brief, sections from each specimen were cut
at 3 to 5 mm, mounted on glass, and dried overnight at 37C. All sections
were then deparaffinized in xylene, rehydrated through a graded alcohol se-
ries, and washed in phosphate-buffered saline. This buffer was used for all
subsequent washes and for dilution of the antibodies. Tissue sections were
heated twice in a microwave oven for 5 minutes each at 700 W in citrate
buffer (pH 6) and then processed with the standard streptavidin–biotin–
immunoperoxidase method (DAKO Universal Kit, DAKO Corporation,
Carpinteria, Calif). Mouse monoclonal antibodies (Santa Cruz Biotechnol-
ogy, Inc. Santa Cruz, Calif) specific for p27 (mouse monoclonal; sc-1641)
and p21 (mouse monoclonal sc-6246) were used at a 1:100 dilution, and
a monoclonal antibody specific for p53 (D01; DAKO Corporation) was
used at a 1:500 dilution. All the primary antibodies were incubated for 1
hour at room temperature. Diaminobenzidine was used as the final chromo-
gen and hematoxylin as the nuclear counterstain. Negative controls for each
tissue section were performed, leaving out the primary antibody. Positive
controls included in each experiment consisted of tissue previously shown
to express the antigen of interest. One pathologist (A.B.) evaluated the stain-
ing pattern of the three proteins separately and scored the protein expression
TABLE 1. Main clinicopathologic features at the time of initial
thymoma resection in patients operated on for recurrences
Variables
Values at initial
thymoma resection
Age, y (mean  standard deviation) 48.1  9.7
Sex ratio (male/female) 14/11
Presence of myasthenia gravis 13 (52%)
Adjacent organ resection 19 (76%)
Postoperative morbidity 9 (36%)
Staging (Masaoka et al5)
I 5 (20%)
II 11 (44%)
III 9 (36%)
WHO classification
A 1 (4%)
AB 2 (8%)
B1 8 (32%)
B2 9 (36%)
B3 5 (20%)
Cell cycle proteins
p21 low expression 9 (36%)
p27 low expression 7 (28%)
p53 high expression 11 (44%)
Double or triple negative combination 8 (32%)
Triple negative combination 5 (20%)
Total 25Cardiovascular Surgery c Volume 138, Number 1 41
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age of tumor cell nuclei staining. All immunoreactive nuclei were regarded
as positive, regardless of staining intensity.
Statistical Analysis
All data were statistically analyzed by SPSS (SPSS 9.05 for Windows,
SPSS Inc, Chicago, Ill). Preliminary descriptive analysis was performed
for the main epidemiologic and pathologic variables to identify anomalous
data.
Interdependence among factors (clinicopathological parameters and cell-
cycle protein expression) was assessed by the c2 test and by Fisher’s exact
test.
Every prognostic variable was correlated for risk of recurrence and of
death. According to our previous report,23 a dichotomized scoring system
was used as follows: p53, p21, and p27 expression in more than 5% of
tumor cells was defined as high expression and was used as a cutoff point.
Survival analysis was set according to the Kaplan–Meier method. Deaths
attributable to cancer were considered as the final event. On the contrary,
those directly depending on myasthenia gravis were considered as deaths
from other cause. Prognostic factors were considered at primary surgery
and at first recurrence resection. The statistical significance of the prognostic
variables was evaluated by the log–rank test. Multivariate analysis was42 The Journal of Thoracic and Cardiovascular Surgperformed with the Cox regression analysis only for those variables that
were significant at univariate analysis.
RESULTS
Postoperative morbidity for recurrence resection was
44%, a significantly higher value than that for original thy-
moma surgery (44% vs 36%; P< .05). Described events
were acute pneumonia (n ¼ 4), pulmonary embolism (n ¼
2), myocardial acute ischemia (n ¼ 2), and respiratory
failure requiring tracheal intubation (n ¼ 3). All myasthenic
patients in this setting had morbidity events. Morbidity also
showed a mild interdependence with the administration of
neoadjuvant therapy (P ¼ .04), extensive reconstruction
(ie, vena cava or diaphragm) (P ¼ .03), and radicality of
the recurrence resection (P ¼ .05).
The comparison between primary and recurrence features
revealed several changes summarized in Table 2. Worsening
of cell-cycle expression was documented in 6 patients. We
also found a worsening of WHO histology in 25% (4/16)ery c July 2009
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Case No. Cell-cycle protein expression changes WHO histology changes
First disease-free
interval (mo)
Interval to second
recurrence (mo) Outcome
1 p21 high/ low AB/ B2 23y 15y Dead
2 p27 high/ low B1/ B3 21* 5y Dead
3 p27 high/ low and p53 low/ high B2/ B3 10* 5* Dead
4 p21 high/ low and p27 high/ low B2/ B3 12* 6* Dead
5 p27 high/ low B3 unchanged 11y 3y Dead
6 p53 low/ high B2 unchanged 18y 4y Alive with disease
Significance with respect to mean values with same initial WHO histology (*P<.05; yP< .01).of the patients with recurrences. All patients with histologic
changes had a worsening of cell-cycle protein expression.
Patients’ outcomes are described in Figure 1. Eight patients
of those undergoing radical resection (8/14, 57%) had a sec-
ond recurrence with the same pattern as the first one (3 me-
diastinal and 5 nonmediastinal) after a mean disease-free
interval of 20  9 months (range 7–44 months). Seven of
these had a third operation, which was radical in 4 patients.
Among those patients who had incomplete resection of the
recurrence, 1 of 4 with complete remission had another re-
currence after 13 months. However, all 4 with partial remis-
sion had progression of the disease or new localization.
Eight patients died after a mean of 35  27 months after
the recurrence surgery. The total number of patients who
died of neoplastic reasons was 5, 2 (40%) in the complete
resection group and 3 (60%) in the other. Other causes of
death were myasthenia complications (n¼ 1), acute myocar-
dic ischemia (n¼ 1), and postradiotherapy pulmonary fibro-
sis (n ¼ 1). Nine patients among those who had a radical
resection of the recurrence and the 4 with total remission
achieved by chemotherapy and radiotherapy after incom-
plete resection are still alive without any evidence of recur-
rent disease.
Overall survival was negatively influenced by the first dis-
ease-free interval being less than 24 months (P ¼ .03) and
by incomplete resection of the recurrence (P ¼ .03) (Fig-
ure 2). Primitive WHO histology (A–AB–B1 vs B2–3) pre-
sented only a mild significance (P ¼ .05), which became
more significant using recurrence histology (P ¼ .03). Pat-
tern of first recurrence was not a significant prognosticator
(P¼ .08); interestingly, we found a slightly better prognosis
in nonmediastinal recurrence. Major organ involvement (ie,
lung, vena cava), presence of local symptoms, and morbidity
rate after the recurrence surgery were not significant.
Cell-cycle expression revealed a significant prognostic
power: survival was significantly lower for p53 high expres-
sion (P ¼ .04), p21 (P ¼ .02), and p27 (P ¼ .003) low ex-
pression (Figure 2). The triple combination of p27 low
expression, p21 low expression, and p53 high expression
was highly predictive of a lower survival (P ¼ .0001). Mul-
tivariate analysis selected triple combination of cell-cycle
protein as the most significant prognostic variable (P ¼The Journal of Thoracic and C.02, odds ratio ¼ 11.96, 95% confidence interval ¼ 1.39–
102.63).
The worsening of cell-cycle protein expression was
highly predictive of bad outcome: all patients who disclosed
a progression of cell-cycle protein expression experienced
a new recurrence and 5 (83%) of these died (Table 2).
DISCUSSION
Although recurrent thymomas represent a subset of neo-
plasms with a more aggressive behavior, these tumors are
slow growing and remain located in the thoracic cavity.
Thus, onemay hypothesize that surgical resection, whenever
feasible, can provide the best cure, and this is what we can
assume from the first analysis of our results. Nevertheless,
despite radical surgical resection, thymomas may recur inde-
pendently from classic clinicopathologic factors.2-4 The dif-
ficulty of having reliable predictive factors interferes with
the planning of common worldwide shared therapeutic pro-
tocols.4,6
We22 have recently investigated the role of the expression
of three key proteins involved in cell-cycle checkpoints in
a large series of well-characterized completely resected thy-
momas.We found a positive correlation between a change of
p27, p21, and p53 expression and the probability of recur-
rence. In this series we have investigated the role of these
key proteins in the prognosis of recurrent thymomas. Our re-
sults suggest a possible role for these proteins in the progno-
sis of the disease. Indeed, all the patients who had a second
recurrence and all the patients who died had at least one al-
tered cell-cycle protein expression. At the multivariate anal-
ysis, the most significant parameter influencing disease-free
survival was the triple combination of high p53, low p21,
and low p27 expression. These findings support the idea
that functional cooperation between different cell-cycle in-
hibitor proteins constitutes another level of regulation in
cell growth control and tumor suppression. It also appears
evident that knowledge of the level of expression of these
factors, and their co–regulation, may be important in predict-
ing patient clinical response to therapy.
Therefore, this article supports the idea that in determin-
ing the therapeutic strategy of patients with recurrent thy-
moma, cell-cycle protein expression should always beardiovascular Surgery c Volume 138, Number 1 43
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General Thoracic Surgery Mineo et alFIGURE 2. Survival analysis for risk factors present at the first recurrence resection. DFI, Disease-free interval.considered to have a more precise indication concerning the
possibility of further recurrence. Cell-cycle protein expres-
sion could be assessed prospectively at the time of initial
thymomectomy to better evaluate the decision of performing
adjuvant therapy, whose use is still debated. In addition, this
information would be helpful in selecting how strict the
follow-up intervals should be.
In as much as the tissue is generally not available for anal-
ysis until after resection and small biopsy specimens are not
adequate, the strategy toward primitive thymomas remains
the same: radical surgical resection as the first step. How-
ever, the status of cell-cycle protein expression can be as-
sessed retrospectively, whenever the initial thymomatous
tissue embedded in paraffin is available. This may take on
a very important role in choosing the most appropriate ther-
apy for a recurrence. In the case of an aggressive recurrence
involving several thoracic organs and requiring extensive re-The Journal of Thoracic and Cardiovascular Sursection to reach oncologic radicality, the knowledge of the
cell-cycle protein expression could be ‘‘the feather that in-
clines the scale’’ in one direction rather than another.
Pattern of recurrence, invasion of vital organs, or need for
major resection cannot be considered a factor per se capable
of limiting radical surgery, which should be pursued as the
primary goal. Nevertheless, the presence of biological ag-
gressive markers since the initial thymomectomy and the
evidence of changes in the recurrent thymoma related to
poorer prognosis should allow the surgeon to reconsider the
therapeutic strategy associating adjuvant–neoadjuvant treat-
ment and, in the near future, newmolecular targeted devices.
The data presented in this report support this hypothesis; the
number of observations is too small to dictate precise rules,
but undoubtedly this field should have more attention in the
near future with the development of multicentric and pro-
spective studies.gery c July 2009
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in 199916 proved to have a clinical and prognostic value.24
Inoue and associates25 suggested that the WHO histotypes
are somewhat correlated with genetic alterations: A–AB
histotypes are biologically distinct from the others whereas
B2–B3 histotypes show tumor progression. In our series, we
demonstrated only a mild significance at univariate analysis.
This is probably due to the small sample size. Nevertheless,
results became more significant when using the recurrence
specimen, owing to the described phenomenon of histologic
type change. The shift of thymoma histology into more ag-
gressive variants in the case of recurrence is a widely known
finding.26 One could suppose that these changes might be
due to a problem of sample interpretation, too small speci-
mens retrieved at the time of recurrence, or artifacts caused
by preoperative radiotherapy, although these possibilities do
not seem applicable in our series.
Interestingly, we found that changes of WHO histotypes
are often associated with the worsening of cell-cycle protein
expression. In addition, these variations of expression are
also associated with a higher probability of recurrence and
a poor prognosis. As a matter of fact, all patients who dis-
played a progression of cell-cycle protein expression had an-
other recurrence, and the vast majority died after a short time.
At this moment in time, the relationship between changes in
cell-cycle protein expression and histologic typing can only
be described. Any further explanation should be clarified
with the better understanding of the mechanism underlying
cell replication. The importance of an altered cell-cycle con-
trol seems to be intuitive in neoplasm onset and growth.
We acknowledge the three main limitations to our study.
First is the retrospective nature of the study, which is quite
mandatory owing to the relative rarity of the primitive dis-
ease and the sporadicity of the recurrences. Second, the lim-
ited quantity of sample tissues did not allow the assessment
of the expression of other cell-cycle proteins. Third, the fol-
low-up in this study was not long enough for a low-malig-
nant though recurrent disease.
In conclusion, we found that cell-cycle protein expression,
namely the combination of high p53, low p21, and low p27
expression, may have a potential prognostic importance in re-
current intrathoracic thymomas. As directed by practical
guidelines, we still consider complete surgical resection,
whenever feasible, as the first choice of treatment in this set-
ting. However, the knowledge of first disease-free interval,
WHO histology, and cell-cycle protein expression will help
in decision making, especially in the case of important neo-
plastic invasion demanding extensive resections.
We thank Dr Giulia Musolino for editing this manuscript.
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